Detecting factor XIa in immune globulin products: Commutability of international reference materials for traditional and global hemostasis assays.
blood coagulation tests
calibration
coagulation factor XIa
immune globulin
thrombin
Journal
Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
07
08
2020
revised:
21
10
2020
accepted:
03
11
2020
entrez:
4
2
2021
pubmed:
5
2
2021
medline:
5
2
2021
Statut:
epublish
Résumé
Activated coagulation factor XIa (FXIa) is an impurity and primary source of procoagulant activity in thrombosis-implicated immune globulin (IG) products. Several assays, of varying quality and precision are used to assess FXIa-like procoagulant activity in units relevant to their respective principles. To advance unified reporting, we sought to employ the World Health Organization reference reagents (RRs) to present the results of differing methodologies in units of FXIa activity and rank the sensitivity and robustness of these methodologies. RR 11/236 served as a calibrator in several FXIa-sensitive blood coagulation tests: two commercial chromogenic FXIa assays (CAs); a nonactivated partial thromboplastin time (NaPTT); an in-house fibrin generation (FG) assay; an in-house thrombin generation (TG) assay; and an assay for FXIa- and kallikrein-like proteolytic activities based on cleavage of substrate SN13a. Some assays were tested in either normal or FXI-deficient plasma. Each method demonstrated a sigmoidal dose-response to RRs. NaPTT was the least sensitive to FXIa and the least precise; our in-house TG was the most sensitive; and the two CAs were the most precise. All methods, except for SN13a, which is less specific for thrombotic impurities, gave comparable (within 20% difference) FXIa activity assignments for IG lots. Purified FXIa reference standards support quantitation of FXIa levels in IG products in all tested assay methodologies. This should help to standardize the measurement of thrombotic potentials in IG products and prevent products exhibiting high procoagulant activity from distribution for patient use. Further research is needed to address the effect of IG product-specific matrixes on assay performance.
Sections du résumé
BACKGROUND
BACKGROUND
Activated coagulation factor XIa (FXIa) is an impurity and primary source of procoagulant activity in thrombosis-implicated immune globulin (IG) products. Several assays, of varying quality and precision are used to assess FXIa-like procoagulant activity in units relevant to their respective principles.
OBJECTIVES
OBJECTIVE
To advance unified reporting, we sought to employ the World Health Organization reference reagents (RRs) to present the results of differing methodologies in units of FXIa activity and rank the sensitivity and robustness of these methodologies.
METHODS
METHODS
RR 11/236 served as a calibrator in several FXIa-sensitive blood coagulation tests: two commercial chromogenic FXIa assays (CAs); a nonactivated partial thromboplastin time (NaPTT); an in-house fibrin generation (FG) assay; an in-house thrombin generation (TG) assay; and an assay for FXIa- and kallikrein-like proteolytic activities based on cleavage of substrate SN13a. Some assays were tested in either normal or FXI-deficient plasma.
RESULTS
RESULTS
Each method demonstrated a sigmoidal dose-response to RRs. NaPTT was the least sensitive to FXIa and the least precise; our in-house TG was the most sensitive; and the two CAs were the most precise. All methods, except for SN13a, which is less specific for thrombotic impurities, gave comparable (within 20% difference) FXIa activity assignments for IG lots.
CONCLUSIONS
CONCLUSIONS
Purified FXIa reference standards support quantitation of FXIa levels in IG products in all tested assay methodologies. This should help to standardize the measurement of thrombotic potentials in IG products and prevent products exhibiting high procoagulant activity from distribution for patient use. Further research is needed to address the effect of IG product-specific matrixes on assay performance.
Identifiants
pubmed: 33537546
doi: 10.1002/rth2.12467
pii: S2475-0379(22)01318-8
pmc: PMC7845073
doi:
Types de publication
Journal Article
Langues
eng
Pagination
211-222Informations de copyright
Published 2020. This article is a U.S. Government work and is in the public domain in the USA. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).
Références
J Thromb Haemost. 2015 Dec;13(12):2168-79
pubmed: 26414338
Baillieres Clin Haematol. 1996 Jun;9(2):355-68
pubmed: 8800510
Thromb Haemost. 2008 Jan;99(1):142-9
pubmed: 18217146
Blood. 2006 Dec 15;108(13):4045-51
pubmed: 16931632
Am J Hematol. 2013 Dec;88(12):1035-40
pubmed: 23907744
Thromb Res. 2018 Jan;161:94-105
pubmed: 29223926
Thromb J. 2013 Jul 05;11(1):12
pubmed: 23829491
Expert Opin Ther Pat. 2020 Jan;30(1):39-55
pubmed: 31847619
J Thromb Thrombolysis. 2011 Aug;32(2):129-37
pubmed: 21614454
Thromb Haemost. 1997 Oct;78(4):1193-201
pubmed: 9364984
Inflamm Bowel Dis. 2010 Sep;16(9):1447-8
pubmed: 20049947
Blood. 2008 Apr 15;111(8):4113-7
pubmed: 18268095
Cerebrovasc Dis. 2010;29(5):497-502
pubmed: 20299790
Thromb Res. 2013 Sep;132(3):374-80
pubmed: 23953593
J Thromb Haemost. 2006 Sep;4(9):1982-8
pubmed: 16961605
Expert Opin Ther Pat. 2016;26(3):323-45
pubmed: 26881476
Lancet. 1986 Jul 26;2(8500):217-8
pubmed: 2873457
Am J Clin Pathol. 2006 Sep;126(3):411-5
pubmed: 16880142
Thromb Res. 2014 Dec;134(6):1328-34
pubmed: 25288467
Haemophilia. 2017 May;23(3):466-475
pubmed: 28205396
Transfusion. 2012 Oct;52(10):2113-21
pubmed: 22448967
Vox Sang. 2012 Jan;102(1):40-6
pubmed: 21545600
Thromb Haemost. 2011 Feb;105(2):269-73
pubmed: 21057700
Blood. 2010 Nov 25;116(22):4684-92
pubmed: 20807891
Transfusion. 2014 Oct;54(10):2553-65
pubmed: 24804899